NASDAQ:REGN

Regeneron Pharmaceuticals Competitors

$502.60
+7.96 (+1.61 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$495.86
Now: $502.60
$506.87
50-Day Range
$446.73
MA: $471.05
$496.01
52-Week Range
$441.00
Now: $502.60
$664.64
Volume1.17 million shs
Average Volume1.02 million shs
Market Capitalization$53.84 billion
P/E Ratio18.37
Dividend YieldN/A
Beta0.3

Competitors

Regeneron Pharmaceuticals (NASDAQ:REGN) Vs. AMGN, GILD, VRTX, BIIB, ALXN, and SGEN

Should you be buying REGN stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Regeneron Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), and Seagen (SGEN).

Regeneron Pharmaceuticals (NASDAQ:REGN) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Profitability

This table compares Regeneron Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Amgen29.42%95.55%15.52%

Analyst Recommendations

This is a breakdown of current recommendations for Regeneron Pharmaceuticals and Amgen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051412.80
Amgen091402.61

Regeneron Pharmaceuticals presently has a consensus price target of $646.2609, suggesting a potential upside of 28.58%. Amgen has a consensus price target of $261.0476, suggesting a potential upside of 2.09%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and Amgen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.85$2.12 billion$21.4723.41
Amgen$23.36 billion6.30$7.84 billion$14.8217.25

Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Regeneron Pharmaceuticals beats Amgen on 9 of the 14 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Profitability

This table compares Regeneron Pharmaceuticals and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Gilead Sciences5.48%37.77%12.76%

Analyst Recommendations

This is a breakdown of current recommendations for Regeneron Pharmaceuticals and Gilead Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051412.80
Gilead Sciences191302.52

Regeneron Pharmaceuticals presently has a consensus price target of $646.2609, suggesting a potential upside of 28.58%. Gilead Sciences has a consensus price target of $97.92, suggesting a potential upside of 46.43%. Given Gilead Sciences' higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Regeneron Pharmaceuticals.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and Gilead Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.85$2.12 billion$21.4723.41
Gilead Sciences$22.45 billion3.75$5.39 billion$6.1410.89

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Regeneron Pharmaceuticals beats Gilead Sciences on 9 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Profitability

This table compares Regeneron Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Vertex Pharmaceuticals38.51%28.55%20.68%

Analyst Recommendations

This is a breakdown of current recommendations for Regeneron Pharmaceuticals and Vertex Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051412.80
Vertex Pharmaceuticals042112.88

Regeneron Pharmaceuticals presently has a consensus price target of $646.2609, suggesting a potential upside of 28.58%. Vertex Pharmaceuticals has a consensus price target of $293.1250, suggesting a potential upside of 33.61%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and Vertex Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.85$2.12 billion$21.4723.41
Vertex Pharmaceuticals$4.16 billion13.64$1.18 billion$4.2951.14

Regeneron Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Regeneron Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and Biogen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.85$2.12 billion$21.4723.41
Biogen$14.38 billion2.86$5.89 billion$33.578.05

Biogen has higher revenue and earnings than Regeneron Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Regeneron Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Biogen35.63%51.00%23.54%

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Regeneron Pharmaceuticals and Biogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051412.80
Biogen5141202.23

Regeneron Pharmaceuticals presently has a consensus price target of $646.2609, suggesting a potential upside of 28.58%. Biogen has a consensus price target of $303.5862, suggesting a potential upside of 12.31%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Biogen.

Summary

Regeneron Pharmaceuticals beats Biogen on 9 of the 15 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Insider and Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Alexion Pharmaceuticals and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion7.21$2.40 billion$9.7416.80
Regeneron Pharmaceuticals$7.86 billion6.85$2.12 billion$21.4723.41

Alexion Pharmaceuticals has higher earnings, but lower revenue than Regeneron Pharmaceuticals. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alexion Pharmaceuticals and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Risk & Volatility

Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Alexion Pharmaceuticals and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals017412.27
Regeneron Pharmaceuticals051412.80

Alexion Pharmaceuticals presently has a consensus target price of $153.4286, suggesting a potential downside of 6.26%. Regeneron Pharmaceuticals has a consensus target price of $646.2609, suggesting a potential upside of 28.58%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Summary

Regeneron Pharmaceuticals beats Alexion Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Insider and Institutional Ownership

87.2% of Seagen shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Seagen and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seagen$916.71 million28.78$-158,650,000.00($1.33)-109.40
Regeneron Pharmaceuticals$7.86 billion6.85$2.12 billion$21.4723.41

Regeneron Pharmaceuticals has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Seagen and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seagen25.34%20.46%16.67%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Risk & Volatility

Seagen has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Seagen and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seagen161112.63
Regeneron Pharmaceuticals051412.80

Seagen presently has a consensus target price of $185.3571, suggesting a potential upside of 27.39%. Regeneron Pharmaceuticals has a consensus target price of $646.2609, suggesting a potential upside of 28.58%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Seagen.

Summary

Regeneron Pharmaceuticals beats Seagen on 9 of the 14 factors compared between the two stocks.

Ad Legacy Research
Breaking Now: Biden's Disturbing Plan to "Reset" America
The “Great Reset” started on January 20th with the inauguration of Joe Biden. Between now and the midterms, the American economy could be reshaped forever – and renowned analyst Jeff Brown has found the “lynchpin” to the entire plan.

Regeneron Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$255.71+0.2%$147.24 billion$23.36 billion20.62Insider Selling
Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.8$66.87+1.6%$84.19 billion$22.45 billion68.94Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$219.39+0.8%$56.78 billion$4.16 billion27.70Analyst Revision
News Coverage
Biogen logo
BIIB
Biogen
1.9$270.31+0.0%$41.18 billion$14.38 billion8.95Upcoming Earnings
Analyst Revision
News Coverage
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$163.68+3.8%$35.98 billion$4.99 billion38.24Unusual Options Activity
News Coverage
Gap Down
Seagen logo
SGEN
Seagen
1.7$145.50+2.8%$26.38 billion$916.71 million57.28Increase in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$130.04+0.4%$21.99 billion$876.29 million-58.84News Coverage
Incyte logo
INCY
Incyte
1.7$82.68+0.6%$18.18 billion$2.16 billion-52.66
Novavax logo
NVAX
Novavax
1.2$227.35+11.1%$16.79 billion$18.66 million-43.55Gap Up
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$138.88+0.1%$16.29 billion$219.75 million-17.74
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$79.40+0.8%$14.44 billion$1.70 billion18.17News Coverage
Repligen logo
RGEN
Repligen
1.5$213.30+0.1%$11.68 billion$270.24 million260.12
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$96.58+1.6%$9.13 billion$788.10 million103.85Analyst Upgrade
Increase in Short Interest
Analyst Revision
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.73+1.0%$9.07 billion$1.45 billion19.27Analyst Report
Exelixis logo
EXEL
Exelixis
1.9$23.59+1.5%$7.36 billion$967.78 million49.15
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.41+0.5%$6.65 billion$195.99 million290.06Insider Selling
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78+0.6%$5.74 billion$1.12 billion84.96Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64+4.1%$4.16 billion$1.11 billion24.96Analyst Report
Gap Up
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90+3.2%$3.98 billion$806.43 million-9.33Analyst Report
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54+1.3%$3.25 billion$36.13 million-69.46News Coverage
Gap Down
Alkermes logo
ALKS
Alkermes
1.2$19.87+0.5%$3.16 billion$1.17 billion-43.19Insider Selling
OPKO Health logo
OPK
OPKO Health
1.9$4.34+0.5%$2.91 billion$901.90 million-24.11Gap Up
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94+3.9%$2.63 billion$182.24 million-8.64Analyst Upgrade
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23+0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.31+5.3%$2.05 billion$638.60 million-10.50
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$124.77+1.5%$2.00 billionN/A-11.27
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$11.24+0.9%$2.00 billion$48.83 million-14.79Analyst Report
News Coverage
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.61+2.2%$1.71 billion$428.41 million15.38News Coverage
Gap Down
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.48+2.5%$1.65 billion$102.43 million-19.13Analyst Upgrade
Codexis logo
CDXS
Codexis
1.3$23.60+4.0%$1.52 billion$68.46 million-67.43Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52+2.4%$1.50 billion$82.27 million-18.34News Coverage
Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99+1.2%$1.24 billion$35.22 million-8.02News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.90+0.1%$1.21 billion$261.02 million6.07
Curis logo
CRIS
Curis
1.3$11.49+6.3%$1.05 billion$10 million-14.01Increase in Short Interest
MannKind logo
MNKD
MannKind
1.4$4.18+2.9%$1.04 billion$63.04 million-19.90Increase in Short Interest
Gap Down
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$23.55+0.0%$932.93 million$3.57 million-10.56Analyst Upgrade
Gap Down
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.67+0.7%$914.90 million$227.19 million46.31Analyst Upgrade
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$22.36+8.8%$812.29 millionN/A0.00Analyst Report
Gap Down
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.05+3.2%$728.99 million$322.07 million-4.81Decrease in Short Interest
News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.33+2.7%$716.63 million$150,000.00-4.76
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.28+1.3%$669.56 million$252 million-2.07High Trading Volume
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.98+2.0%$625.09 million$143.01 million-1.14
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.58+5.6%$609.03 million$59.29 million-23.87Increase in Short Interest
News Coverage
Gap Down
Agenus logo
AGEN
Agenus
1.6$2.62+1.5%$536.28 million$150.05 million-2.40News Coverage
Geron logo
GERN
Geron
1.4$1.47+2.7%$468.24 million$460,000.00-4.20Decrease in Short Interest
News Coverage
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.00+0.7%$461.18 million$109.33 million-2.21
Verastem logo
VSTM
Verastem
1.3$2.68+0.4%$460.07 million$17.46 million-1.90
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.12+7.3%$455.14 million$22.27 million-3.98Analyst Report
Insider Buying
Analyst Revision
News Coverage
Gap Down
XOMA logo
XOMA
XOMA
1.3$37.50+0.9%$422.18 million$18.37 million-33.78Increase in Short Interest
News Coverage
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$4.12+7.8%$391.02 million$36.63 million-4.85Gap Up
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.